Coherus Oncology (CHRS) vs Korro Bio (KRRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Coherus Oncology (CHRS) has outperformed Korro Bio (KRRO) over the past year, losing 40.9% versus a loss of 78.5%. Over five years, CHRS leads with a -94.1% price change compared with -97.0% for KRRO. Coherus Oncology is the larger company by market cap ($156.0 million vs $154.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CHRS | KRRO |
|---|---|---|
| Share price | $1.01 | $10.49 |
| Market cap | $156.05M | $154.47M |
| 1-day change | -1.94% | +7.48% |
| YTD return | -28.87% | +30.96% |
| 1-year return | -40.94% | -78.49% |
| 5-year return | -94.06% | -97.05% |
| EPS (TTM) | $-1.25 | $-10.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.62 | $55.89 |
| 52-week low | $1.01 | $5.20 |
| Distance from 52-week high | -61.39% | -81.23% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +667.33% | +92.56% |
| Average volume | 1.14M | 148.67K |
| Shares outstanding | 154.50M | 14.73M |
| Employees | 144 | 57 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CHRS has outperformed KRRO by 37.6 percentage points over the past year.
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Healthcare · Biotechnology · 144 employees
About Korro Bio
KRRO stock →Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.
Healthcare · Biotechnology · 57 employees
CHRS vs KRRO FAQ
Which is bigger, Coherus Oncology or Korro Bio?
Coherus Oncology (CHRS) is larger, with a market capitalization of $156.05M compared with $154.47M for Korro Bio (KRRO).
Which stock has performed better over the past year, CHRS or KRRO?
CHRS returned -40.94% over the past 12 months, compared with -78.49% for KRRO (price return, excluding dividends). Past performance does not predict future results.
Are Coherus Oncology and Korro Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.